Farrell Simon Biography and Net Worth

Insider of Trevi Therapeutics

Farrell Simon, Pharm.D. has served as our Chief Commercial Officer since February 2023. Prior to that, he served as our Senior Vice President, Head of Commercial and Strategy, from February 2022 until February 2023 and Vice President, Head of US Marketing, from September 2020 until February 2022. Previously, Dr. Simon was the Senior Director, Chief of Staff to the Biopharma Group President at Pfizer Inc. and a member of the biopharma executive leadership team from January 2018 to September 2020. Prior to joining Pfizer, Dr. Simon gained general management, marketing, and medical affairs experience at Procter & Gamble. Dr. Simon is the founder and Chief Executive Officer of The Simon Cancer Foundation and is on the board of directors for the Greater New Haven Chamber of Commerce. He previously held positions on the advisory boards for the business school and the College of Pharmacy at the University of Florida. Dr. Simon holds both an M.B.A. and a Pharm.D. from the University of Florida.

What is Farrell Simon's net worth?: The estimated net worth of Farrell Simon is at least $1.04 million as of March 10th, 2025. Dr. Simon owns 76,900 shares of Trevi Therapeutics stock worth more than $1,035,843 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Simon may own. Learn More about Farrell Simon's net worth.
How do I contact Farrell Simon?: The corporate mailing address for Dr. Simon and other Trevi Therapeutics executives is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. Trevi Therapeutics can also be reached via phone at (203) 304-2499 and via email at [email protected]. Learn More on Farrell Simon's contact information.
Has Farrell Simon been buying or selling shares of Trevi Therapeutics?: Farrell Simon has not been actively trading shares of Trevi Therapeutics during the past quarter. Most recently, Farrell Simon sold 81,313 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a transaction totalling $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares of the company's stock, valued at $519,075. Learn More on Farrell Simon's trading history.
Who are Trevi Therapeutics' active insiders?: Trevi Therapeutics' insider roster includes Lisa Delfini (CFO), Jennifer Good (Co-Founder, President and CEO), David Meeker (Director), Thomas Sciascia (Co-Founder, Chief Scientific Officer), and Farrell Simon (Insider). Learn More on Trevi Therapeutics' active insiders.
Are insiders buying or selling shares of Trevi Therapeutics?: In the last year, insiders at the sold shares 2 times. They sold a total of 86,576 shares worth more than $583,493.29. The most recent insider tranaction occured on March, 21st when CEO Jennifer L Good sold 5,263 shares worth more than $34,630.54. Insiders at Trevi Therapeutics own 18.3% of the company. Learn More about insider trades at Trevi Therapeutics.
Information on this page was last updated on 3/21/2025.

Farrell Simon Insider Trading History at Trevi Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2025	Sell	81,313	$6.75	$548,862.75	76,900

Farrell Simon Buying and Selling Activity at Trevi Therapeutics

Trevi Therapeutics Company Overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $13.47

$13.35

$14.00

50 Day Range

MA: $10.97

$8.77

$13.70

2 Week Range

Now: $13.47

$2.36

$14.00

Volume

2,803,945 shs

Average Volume

1,989,890 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83